Shimla Online

Fuchs Endothelial Corneal Dystrophy Market Size is anticipated to increase during the study period 2019-2032

 Breaking News
  • No posts were found

Fuchs Endothelial Corneal Dystrophy Market Size is anticipated to increase during the study period 2019-2032

November 15
23:36 2022
Fuchs Endothelial Corneal Dystrophy Market Size is anticipated to increase during the study period 2019-2032

The Fuchs Endothelial Corneal Dystrophy market report provides current treatment practices, emerging drugs, Fuchs Endothelial Corneal Dystrophy market share of the individual therapies, current and forecasted Fuchs Endothelial Corneal Dystrophy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Fuchs Endothelial Corneal Dystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Fuchs Endothelial Corneal Dystrophy market.

 

Key takeaways from the Fuchs Endothelial Corneal Dystrophy Market Research Report

  • The increase in Fuchs Endothelial Corneal Dystrophy market size is a direct consequence of expected approval of emerging therapies and improved understanding and growing awareness of Fuchs Endothelial Corneal Dystrophy in the 7MM.
  • According to DelveInsight’s analysis, FECD is more prominent in females in comparison to males.
  • Fuchs Endothelial Corneal Dystrophy Market Companies are working such as Kowa Pharmaceuticals, Trefoil Therapeutics, ProQR Therapeutics, Emmecell, and others.
  • Fuchs Endothelial Corneal Dystrophy Pipeline therapies such as Ripasudil (K-321), TTHX 1114, STN1010904/AE-001, EO2002, and others

 

For further information on the market impact by therapies, download the Fuchs Endothelial Corneal Dystrophy sample @ Fuchs Endothelial Corneal Dystrophy Market Size

 

Fuchs Endothelial Corneal Dystrophy Overview

Fuchs endothelial corneal dystrophy is the most common form of corneal dystrophy. It is an inherited condition caused by changes in various genes, which lead to the abnormal function of the innermost layer of the cornea, the endothelium. The endothelium is made up of a single layer of cells (endothelial cells) which rest on a thin membrane (Descemet’s membrane). Endothelial cells normally function to keep the cornea clear and transparent by pumping fluid out of the stroma (the thick middle layer of the cornea). A small number of endothelial cells are normally lost when a person gets older but in Fuchs dystrophy this process is accelerated, causing the cornea to swell and become cloudy (corneal oedema), which in turn makes vision blurry. Most patients do not experience any symptoms when the first sign of Fuchs dystrophy is detected (known as corneal guttata), often by an optician during a routine eye check.

 

Recent Developmental Activities in the Fuchs Endothelial Corneal Dystrophy Market

  • TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer. In addition to the trial in patients undergoing DSO surgery, the company is conducting a Phase 1/2 trial (“INTREPID”) to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to corneal endothelial disorders, including FECD.
  • Ripasudil hydrochloride hydrate is a rho-kinase inhibitor, it has been suggested that the compound may also act on other kinases in the eye, leading to investigations of its applicability to other ophthalmic diseases. As part of these efforts, development of the compound as a treatment for Fuchs endothelial corneal dystrophy (FECD) is underway.

 

Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation in the 7MM

  • Total Fuchs endothelial corneal dystrophy Prevalent Cases
  • Fuchs endothelial corneal dystrophy Gender-specific Cases

 

Keen to learn how Fuchs endothelial corneal dystrophy Market Trends are going to appear in 2032 for the 7MM, Download @ Fuchs endothelial corneal dystrophy Market Outlook

 

Fuchs Endothelial Corneal dystrophy Treatment Market

FECD is slowly progressive, and typically patients do not seek treatment until the endothelial layer is badly degenerated. Transplantation is the only current treatment and there are no FDA-approved pharmacological therapies available for FECD. The early treatment is usually in the form of hypertonic saline eye drops or ointments that stabilizes or improve vision by drawing extra water out of the cornea. Other supportive treatments and surgical procedures such as phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps can be used to relieve painful symptoms, especially those associated with ruptured bullae in later stages of the disease. More recent approach to manage is the topical use of a ROCK inhibitor to speed up recovery and increase endothelial cell density than happens with DSO alone. Rhopressa is used as an off-label usage for FECD.

 

Fuchs Endothelial Corneal dystrophy Emerging Therapies

  • Ripasudil (K-321)
  • TTHX1114
  • STN1010904/AE-001
  • EO2002

 

Know more about the driving forces and restraining factors @ Fuchs Endothelial Corneal dystrophy Companies

 

Scope of the Fuchs Endothelial Corneal dystrophy Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Fuchs Endothelial Corneal Dystrophy Market Companies- Kowa Pharmaceuticals, Trefoil Therapeutics, ProQR Therapeutics, Emmecell, and others.
  • Fuchs Endothelial Corneal Dystrophy Pipeline therapies- Ripasudil (K-321), TTHX 1114, STN1010904/AE-001, EO2002, and others
  • Fuchs Endothelial Corneal Dystrophy Market Barriers and Drivers
  • Fuchs Endothelial Corneal Dystrophy Unmet Needs

 

Table of Content

1. Key Insights

2. Executive Summary of Fuchs Endothelial Corneal Dystrophy (FECD)

3. Competitive Intelligence Analysis for Fuchs Endothelial Corneal Dystrophy (FECD)

4. Fuchs Endothelial Corneal Dystrophy (FECD): Market Overview at a Glance

5. Fuchs Endothelial Corneal Dystrophy (FECD): Disease Background and Overview

6. Patient Journey

7. Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Fuchs Endothelial Corneal Dystrophy (FECD) Unmet Needs

10. Key Endpoints of Fuchs Endothelial Corneal Dystrophy (FECD) Treatment

11. Fuchs Endothelial Corneal Dystrophy (FECD) Marketed Products

12. Fuchs Endothelial Corneal Dystrophy (FECD) Emerging Therapies

13. Fuchs Endothelial Corneal Dystrophy (FECD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Fuchs Endothelial Corneal Dystrophy (FECD)

17. KOL Views

18. Fuchs Endothelial Corneal Dystrophy Market Drivers

19. Fuchs Endothelial Corneal Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Interested in knowing the Fuchs Endothelial Corneal Dystrophy market by 2032? Click to get a snapshot of the Fuchs Endothelial Corneal Dystrophy Market Research Report

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles